Tesamorelin (5mg/10mg)
GHRH Peptide Studied for Visceral Fat Reduction
Order Tesamorelin (5mg/10mg) online for laboratory research. Compare the listed vial options and current price, then add your selection to cart and continue to checkout. Review available COA records for the exact product, strength and lot. Research Use Only; not for human or veterinary use.
Tesamorelin is listed for growth hormone laboratory research. Catalog vial contents are 5mg / 10mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- Visceral fat reduction research
- Liver fat reduction
- Enhanced stability
What is Tesamorelin?
A GHRH analog studied in clinical trials of visceral and liver fat reduction.
Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
What mechanisms are being studied?
Tesamorelin is a full-length GHRH(1-44) analog with a trans-3-hexenoic acid modification at the N-terminus, providing enhanced stability and resistance to enzymatic degradation. It is FDA-approved (Egrifta) for reducing excess abdominal fat in adults with HIV-associated lipodystrophy; other uses are investigational.
What are the research questions?
- HIV-associated lipodystrophy: FDA-approved as Egrifta® for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy.
- MASLD/NASH (liver fat): The T-LIFT trial demonstrated 37% reduction in hepatic fat fraction.
- Visceral fat reduction: Specifically targets metabolically dangerous visceral adipose tissue.
- Cognitive function: The STAY trial showed significant improvements in executive function and verbal memory.
What does the published work describe?
Falutz J et al. (JAMA 2007) — 18% visceral fat reduction vs 2% increase with placebo at 26 weeks. Fourman LT et al. (Lancet Diabetes Endocrinol 2020) — T-LIFT: 37% liver fat reduction. STAY trial — Improved executive function composite scores. FDA-approved with comprehensive Phase 3 safety data.
What are the limits of this evidence?
The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.
Study references
- Falutz J et al. JAMA 2007;298(22):2651-2662
- Fourman LT et al. Lancet Diabetes Endocrinol 2020
These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is Tesamorelin handled in the lab?
For Tesamorelin, record the product code TESA, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
Choose a solvent for Tesamorelin from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay.
For Tesamorelin, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists 5135.83 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied Tesamorelin form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A Tesamorelin laboratory protocol should record identity, product code TESA, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- Tesamorelin
- CAS Number
- 218949-48-5
- Molecular Weight
- 5135.83 g/mol
- HPLC Purity Specification
- ≥98%
- Category
- Growth Hormone
- Starting Price
- $59.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Tesamorelin has a catalog purity specification of ≥98%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin is listed for growth hormone laboratory research. Catalog vial contents are 5mg / 10mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of Tesamorelin are available?
The catalog lists 5mg / 10mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret Tesamorelin purity results?
Tesamorelin has a catalog purity specification of ≥98%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should Tesamorelin be handled in the laboratory?
For Tesamorelin, record the product code TESA, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for Tesamorelin?
Choose a solvent for Tesamorelin from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay.
How do I calculate a Tesamorelin stock concentration?
For Tesamorelin, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists 5135.83 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should Tesamorelin be stored after preparation?
Use the documented storage conditions for the supplied Tesamorelin form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a Tesamorelin lab protocol document?
A Tesamorelin laboratory protocol should record identity, product code TESA, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this Tesamorelin product?
Fmoc and Boc are peptide protecting-group strategies, not proof of how this Tesamorelin lot was made. For sequence-defined peptides, synthesis review can examine deletion products, incomplete deprotection and modifications using the method and matching analytical evidence. A single chromatographic peak does not by itself establish sequence.
Is Tesamorelin for human use?
No. Tesamorelin is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
